Elsilimomab (also known as B-E8) is a mouse monoclonal antibody. B-E8 was developed by Diaclone,  a French company which produces many mouse monoclonal antibodies.
It (OPR-003) targets (and blocks)
It has undergone a number of early stage clinical trials, e.g. for
lymphoma and myeloma.
It was used as a template to develop a high-affinity, antagonist, fully human
anti-IL-6 mAb 1339.
"WHO Drug Information" (PDF). Archived from the original (PDF) on October 16, 2009. p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer
"Datasheet B-E8 mAb". Diaclone.
"First Fully Human Anti-IL6 Antibody Under Development". Genetic Engineering & Biotechnology News. Oct 2006.
^ a b
Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. (December 2009). "A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma". Clinical Cancer Research. 15 (23): 7144–52. doi: 10.1158/1078-0432.CCR-09-1483. PMC . 2787636 PMID 19934301.